Persistent SARS-CoV-2 infection resolved after B-cell recovery in a patient with follicular lymphoma treated with B-cell depletion therapy

Yuriko Sueda; Hirokazu Tokuyasu; Momoka Atsuta; Hiromitsu Sakai; Katsunori Arai; Chika Esumi; Misato Mochizuki; Tomoki Itohara; Naoki Fujisawa; Akira Yamasaki

Respiratory Medicine Case Reports (Jan 2024)

Persistent SARS-CoV-2 infection resolved after B-cell recovery in a patient with follicular lymphoma treated with B-cell depletion therapy

Yuriko Sueda,
Hirokazu Tokuyasu,
Momoka Atsuta,
Hiromitsu Sakai,
Katsunori Arai,
Chika Esumi,
Misato Mochizuki,
Tomoki Itohara,
Naoki Fujisawa,
Akira Yamasaki

Affiliations

Yuriko Sueda: Respiratory Medicine Division, Matsue Red Cross Hospital, Matsue City, Shimane, Japan
Hirokazu Tokuyasu: Respiratory Medicine Division, Matsue Red Cross Hospital, Matsue City, Shimane, Japan; Corresponding author. Division of Respiratory Medicine, Matsue Red Cross Hospital, 200 Horomachi, Matsue City, Shimane, 690, Japan.
Momoka Atsuta: Respiratory Medicine Division, Matsue Red Cross Hospital, Matsue City, Shimane, Japan
Hiromitsu Sakai: Respiratory Medicine Division, Matsue Red Cross Hospital, Matsue City, Shimane, Japan
Katsunori Arai: Respiratory Medicine Division, Matsue Red Cross Hospital, Matsue City, Shimane, Japan
Chika Esumi: Pathology Division, Matsue Red Cross Hospital, Matsue City, Shimane, Japan
Misato Mochizuki: Pharmacy Division, Matsue Red Cross Hospital, Matsue City, Shimane, Japan
Tomoki Itohara: Clinical Laboratory Division, Matsue Red Cross Hospital, Matsue City, Shimane, Japan
Naoki Fujisawa: Division of Virology, Shimane Prefectural Institute of Public Health and Environmental Science, Matsue City, Shimane, Japan
Akira Yamasaki: Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, School of Medicine, Faculty of Medicine, Tottori University, Yonago City, Tottori, Japan

Journal volume & issue: Vol. 52
p. 102131

Abstract

Read online

A 68-year-old woman with follicular lymphoma was treated with chemotherapy, including the anti-CD20 monoclonal antibody obinutuzumab, and achieved remission. A month after the administration of obinutuzumab, the patient contracted coronavirus disease 2019 (COVID-19), and various antiviral drugs were administered. However, the infection had not been eliminated. One year and three months after chemotherapy, peripheral B cell recovery was achieved, and the infection had resolved. This report provides insight into the course of COVID-19 in patients with impaired humoral immunity.

Published in Respiratory Medicine Case Reports

ISSN: 2213-0071 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system
Website: http://www.journals.elsevier.com/respiratory-medicine-case-reports/

About the journal

Abstract

Keywords